首页 | 本学科首页   官方微博 | 高级检索  
检索        

阿奇霉素与氨苄西林-舒巴坦治疗下呼吸道感染的最小成本分析
引用本文:董华.阿奇霉素与氨苄西林-舒巴坦治疗下呼吸道感染的最小成本分析[J].中国药房,2007,18(14):1050-1052.
作者姓名:董华
作者单位:山东省枣庄市立医院,枣庄市,277102
摘    要:目的:评价注射用阿奇霉素(AZM)与氨苄西林-舒巴坦(AMS)治疗下呼吸道感染的经济性。方法:将100例下呼吸道感染患者随机分为AZM组与AMS组,分别应用AZM、AMS治疗5~7d、7~14d,对2种用药方案进行最小成本分析。结果:AZM组、AMS组平均成本分别为1331·00、3167·39元,差异有统计学意义(P<0·01);总有效率分别为90·0%、84·0%(P>0·05),成本-效果比分别为1478·9、3770·7元。结论:AZM治疗方案较佳。

关 键 词:阿奇霉素  氨苄西林-舒巴坦  最小成本分析  下呼吸道感染
文章编号:1001-0408(2007)14-1050-03
收稿时间:06 20 2006 12:00AM
修稿时间:09 11 2006 12:00AM

Azithromycin and Ampicillin-Sulbactam for Lower Respiratory Infection: Cost-minimization Analysis
DONG Hua.Azithromycin and Ampicillin-Sulbactam for Lower Respiratory Infection: Cost-minimization Analysis[J].China Pharmacy,2007,18(14):1050-1052.
Authors:DONG Hua
Institution:Zaozhuang City Public Hospital in Shandong,Zaozhuang 277102,China
Abstract:OBJECTIVE:To evaluate the economic effects of azithromycin(AZM) and ampicillin/sulbactam(AMS) in trea-ting lower respiratory infection so as to optimize a treatment scheme with better curative effect but lower cost.METHODS:A total of 100 patients with lower respiratory infection were randomly assigned to receive AZM for 5~ 7 days or AMS for 7~ 14d,with cost-minimization analysis conducted on the 2 therapeutic schemes.RESULTS:The average cost for AZM vs.AMS scheme was 1 331.00 vs.3 167.39 yuan,showing significant differences(P<0.01) between 2 schemes.The total effective rate and the cost-effectiveness ratio of AZM vs.AMS scheme were 90.0% vs.84.0%(P>0.05) and 1 478.9 vs.3 770.7,respectively.CONCLUSION:The homemade azithromycin is preferable compared with AMS.
Keywords:Azithromycin  Ampicillin/sulbactam  Cost-minimization analysis  Lower respiratory infection
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号